The Effect of rTMS Over the SMA on Gait Performance in Parkinson's Disease (NCT07190235) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
The Effect of rTMS Over the SMA on Gait Performance in Parkinson's Disease
Hong Kong81 participantsStarted 2026-01-06
Plain-language summary
This study aims to investigate the effects of high-frequency and low-frequency repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) on gait performance, especially gait initiation, in individuals with Parkinson's disease (PD). Furthermore, the investigators will explore the impact of rTMS over the SMA on walking speed, functional mobility, and limits of stability in PD. It is hypothesized that rTMS over the SMA will improve gait performance in PD.
Who can participate
Age range
18 Years – 89 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. diagnosed with PD according to thecriteria set by Movement Disorder Committee,
. with Hoehn and Yahr stages II-III, which are recognized as representing mild to moderate disease severity,
. have self-reported difficulty in gait initiation, assessed by item 5 of the freezing of gait questionnaire (FOGQ),
. have used a dopaminergic medication dose in the last month,
. a minimum score of 23 of 30 points on the Montreal Cognitive Assessment (MoCA).
Exclusion criteria
. patients with unstable medical conditions,
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial uses repetitive TMS applied to the supplementary motor area to try to improve gait — how does that approach relate to what's causing my specific walking or balance problems with Parkinson's, and is my situation likely to be relevant to what they're studying?
2The trial is measuring something called 'anticipatory postural adjustments' at the start of walking — can you explain what that means for me practically, and whether problems with that specific movement are part of what I'm experiencing?
3Since this trial is listed as 'not yet recruiting,' what does that timeline mean for my situation — should I be pursuing other treatments now rather than waiting to see if I might be eligible?
4This study is listed as Phase NA, which often applies to device or non-drug studies — what is currently known about the safety of repetitive TMS over the supplementary motor area for someone with my stage of Parkinson's?
5Are there standard treatments or already-established therapies for gait problems in Parkinson's that I should consider first before looking at a trial that hasn't even started enrolling yet?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in duration of anticipatory postural adjustments (APAs) during gait initiation